BRGS™ mouse models are available and already in use for studies in fields such as:

  • immunology;
  • inflammation;
  • vaccine & drug screening;
  • physiopathology of infectious diseases;
  • personalized medicine;
  • stem cell transplantation;
  • gene therapy;
  • oncology;
  • drug development;

Studies can span from the most early R&D to preclinical safety/efficacy development stages. Performing screening on components of the human immune system in an in vivo context is likely to yield results that will more reliably predict human responses, as compared to those obtained using “standard” rodent models.


AXENIS designs custom-made models that meet the specific needs of its public and private customers. Exploratory work, as well as late preclinical studies, are performed by AXENIS in areas of activity such as:

  • hematopoietic efficacy/safety profiling of drugs and biologicals: covers molecules such as vaccines, adjuvants, biosimilars, small synthetic molecules, monoclonal antibodies, new formulations – in a variety of application fields
  • infectious diseases: humanized mice can support infection by a variety of human-tropic pathogens (e.g. HIV, CMV, RSV, EBV, Dengue virus, HTLV, etc.) and host-pathogens interactions, as well as new therapeutics, can be evaluated directly in BRGS™-HIS mice
  • human antibody discovery: humanized mice mount human antibody responses upon immunization, in theory “at will” against any antigenic target
  • oncology: BRGS™ mice are particularly permissive to human tumor xenograft transplantation, and host-tumor interactions, as well as evaluation of therapeutics that require the presence of both a tumor and human immune cells can be evaluated in BRGS™-HIS mice